Chen Ying, Zhang Zhenhua, Luo Xue, Cen Meini, Dai Peng, Zhu Xiaoyan
Department of Thyroid and Breast Surgery, Xiamen Humanity Hospital, Xiamen, 361006, China.
Department of Breast and Thyroid Surgery, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, 250014, China.
Discov Oncol. 2025 May 8;16(1):692. doi: 10.1007/s12672-025-02485-4.
The progression and metastasis of breast cancer patients are regulated by genetics and epigenetics. Circular RNA (circRNA) plays a pivotal role in modulating the advancement of tumors. The study aimed to explore the clinical performance and regulatory role of hsa-circVIM in breast cancer and its modulatory effect on tamoxifen resistance in hormone receptor (HR) positive breast cancer cells.
RT-qPCR was performed to detect hsa-circVIM expression in breast cancer tissues and cells.CCK-8 assay, Transwell assay, and flow cytometric analyses were performed to evaluate the effects of hsa-circVIM on cellular activities in breast cancer cells and TAM sensitivity in MCF7/TR cells. Bioinformatic analyses were conducted to make function and pathway enrichment analyses.
hsa-circVIM expression was raised in breast cancer and predicted unsatisfactory overall survival outcomes. Silencing of hsa-circVIM suppressed cell viability, and migration capacities, while simultaneously enhancing TAM sensitivity and inducing apoptosis of HR-positive breast cancer cells by targeting miR-1294.
Elevated hsa-circVIM expression in breast cancer suggested its potential as a prognostic biomarker. hsa-circVIM functions as both a cancer-promoting molecule and a regulator of TAM responsiveness in HR-positive breast cancer cells by regulating miR-1294 expression. Therefore, hsa-circVIM serves as a potent biomarker for prognosis, plays a promoting role in breast cancer progression, and may offer a therapeutic avenue to overcome TAM resistance.
乳腺癌患者的进展和转移受遗传学和表观遗传学调控。环状RNA（circRNA）在调节肿瘤进展中起关键作用。本研究旨在探讨hsa-circVIM在乳腺癌中的临床表现和调控作用及其对激素受体（HR）阳性乳腺癌细胞中他莫昔芬耐药性的调节作用。
采用RT-qPCR检测乳腺癌组织和细胞中hsa-circVIM的表达。进行CCK-8检测、Transwell检测和流式细胞术分析，以评估hsa-circVIM对乳腺癌细胞中细胞活性和MCF7/TR细胞中TAM敏感性的影响。进行生物信息学分析以进行功能和通路富集分析。
hsa-circVIM在乳腺癌中表达升高，并预测总体生存结果不佳。沉默hsa-circVIM可抑制细胞活力和迁移能力，同时通过靶向miR-1294增强TAM敏感性并诱导HR阳性乳腺癌细胞凋亡。
乳腺癌中hsa-circVIM表达升高表明其作为预后生物标志物的潜力。hsa-circVIM通过调节miR-1294表达，在HR阳性乳腺癌细胞中既作为促癌分子又作为TAM反应性的调节剂发挥作用。因此，hsa-circVIM作为一种有效的预后生物标志物，在乳腺癌进展中起促进作用，并可能为克服TAM耐药性提供一条治疗途径。
